You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is there any information on the use of Mounjaro® (tirzepatide) in patients with lipedema?
No efficacy or safety data are available for tirzepatide use in lipedema as it has not been studied by Lilly. Lipedema was not an exclusion in clinical trials, but no subanalyses were done to confirm enrollment or outcomes for these patients.
See important safety information, including boxed warning, in the attached prescribing information.
Treatment Recommendations
Eli Lilly and Company cannot provide a recommendation on whether to use tirzepatide in a patient with lipedema. The health care practitioner may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors in developing a treatment plan. The health care practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
Enclosed Prescribing Information
References
Date of Last Review: July 16, 2025